Journal ArticleDOI
Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
TLDR
There is a growing understanding of viral, host and environmental factors influencing disease progression, which ultimately could improve the management of chronic hepatitis B.About:
This article is published in Journal of Hepatology.The article was published on 2008-02-01. It has received 1172 citations till now. The article focuses on the topics: HBeAg & Hepatitis B.read more
Citations
More filters
Journal ArticleDOI
Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases.
Lorenzo Onorato,Mariantonietta Pisaturo,Clarissa Camaioni,Pierantonio Grimaldi,Alessio Vinicio Codella,Federica Calò,Nicola Coppola +6 more
TL;DR: In this paper, the authors provide an overview of the risk of overt or occult HBV reactivation in non-neoplastic patients treated with immunosuppressive drugs, particularly for rheumatological, gastrointestinal, dermatological and neurological diseases, and for COVID-19 patients receiving immunomodulating agents.
Journal ArticleDOI
The natural history of chronic HBV infection
TL;DR: Chronic hepatitis B is a disease of worldwide importance that carries considerable morbidity and mortality and is associated with considerable mortality due to complications of portal hypertension and, most importantly, with the development of hepatocellular carcinoma, which is frequent in patients with CHB.
Journal ArticleDOI
HBV pre‐core mutant in genotype‐D infected children is selected during HBeAg/anti‐HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood
Piero Colombatto,Cristiana Barbera,Flavia Bortolotti,Anna Maria Maina,F. Moriconi,Daniela Cavallone,Pier Luigi Calvo,Filippo Oliveri,Ferruccio Bonino,Ferruccio Bonino,Maurizia Rossana Brunetto +10 more
TL;DR: In conclusion, pre‐C‐mt is selected during HBeAg/anti‐HBe SC in children with poor control of HBV replication, leading to H beAg‐negative chronic‐active‐hepatitis during adulthood.
Journal ArticleDOI
Loss of HBsAg and antiviral treatment: from basics to clinical significance
TL;DR: Serum HBsAg titer may reflect the level of intrahepatic hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in most patients, and vary with natural phases of chronic HBV infection, genotypes and variants, antiviral therapy, and other related factors, which might help establish new concept of more practical “response-guided treatment (RGT)” rules for antiviral treatment.
Book ChapterDOI
Prognostic Factors for Survival in Patients with Liver Cirrhosis
M. Samada,Julio Hernández +1 more
TL;DR: Liver cirrhosis is the final stage of various chronic liver diseases and is essentially morphological, defined as a diffuse alteration of hepatic architecture by the presence of necrosis, fibrosis and regenerative nodules.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Chien-Jen Chen,Hwai I. Yang,Jun Su,C.-L. Jen,San Lin You,Sheng-Nan Lu,Guan-Tarn Huang,Uchenna H. Iloeje +7 more
TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI
Chronic hepatitis B
Anna S. Lok,Brian J. McMahon +1 more
TL;DR: These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV).
Journal ArticleDOI
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
TL;DR: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
Journal ArticleDOI
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
TL;DR: Further studies are needed to investigate other viral factors (eg, HBV genotype/mutant, occult HBV, HIV coinfection) and preventable or treatable comorbidities ( eg, obesity, diabetes) in the HCC risk in cirrhosis.